McKesson’s $5.8 Billion Option Care Deal Puts Home Infusion in Wall Street’s Spotlight -( $MCK $OPCH )

The proposed acquisition offers Option Care Health shareholders a substantial cash premium, and gives McKesson a strategic foothold in delivering complex therapies closer to patients.

McKesson Corporation (NYSE: MCK) and private investment firm Clayton, Dubilier & Rice are making a $5.8 billion enterprise-value bet on a straightforward healthcare proposition: sophisticated treatment does not always require a hospital address. Their agreement to acquire Option Care Health (NASDAQ: OPCH) for $32.05 per share in cash puts a concrete valuation on a national infusion platform—and reinforces McKesson’s push into specialty care delivered in community settings. Announced October 6, the proposed transaction represents an approximately 37% premium to Option Care Health’s October 5 closing price. For many existing shareholders, that is a substantial proposed payday. For McKesson investors, the more intriguing story is what the company intends to own: a meaningful interest in the infrastructure that helps complex medicines reach patients outside traditional hospital settings. Healthcare rarely offers a simple investment narrative. This one at least comes with a clearly printed price tag.

A Premium With Strategic Purpose

Under the agreement, CD&R would own approximately 51% of Option Care Health, while McKesson would invest approximately $1.4 billion for a roughly 49% interest. Option Care would remain a separate business under its existing management team. The companies expect the transaction to close in the first half of calendar 2027, subject to shareholder approval, regulatory clearance and customary closing conditions. The distinction between the headline valuation and McKesson’s commitment matters. The approximately $5.8 billion figure is the transaction’s enterprise value, including debt, not the amount McKesson alone is paying. Independent coverage from Il Sole 24 Ore Radiocor also identifies the deal as a $5.8 billion transaction including debt. The structure gives McKesson substantial economic participation without initially taking majority ownership. It also establishes a framework for a future acquisition of CD&R’s interest, although that next step would depend on specified conditions and regulatory approvals. This is a potential route to greater ownership, not a promise that McKesson will ultimately acquire the entire company. The bullish interpretation is that McKesson is securing both exposure to an established platform and room to deepen that investment later. It is buying a seat at the table before deciding whether to purchase the dining room.

The Business Behind The Bid

Option Care Health brings operating scale, not merely an appealing healthcare theme. The company reported 2025 net revenue of approximately $5.65 billion, up 13% from the previous year. That historical performance provides a tangible foundation for the acquisition story: the buyers are pursuing a business that had already demonstrated substantial revenue growth before the announcement, Its reach is equally important. Option Care describes itself as the nation’s largest independent provider of home and alternate-site infusion services, with more than 8,000 team members, including more than 5,000 clinicians, serving patients across all 50 states. Those figures help explain the strategic appeal. A national clinical network is more than a collection of treatment locations; it is an operating platform through which specialized therapies can reach patients. McKesson specifically identified Option Care’s home and ambulatory infusion footprint as aligned with its priorities of expanding access to complex treatments in lower-cost community settings. The investment thesis therefore rests on an existing business, an established care-delivery network and a buyer with a stated interest in expanding specialty services. That is a sturdier foundation than a presentation slide featuring an enormous addressable market and a conveniently tiny footnote.

Why McKesson Investors Should Care

McKesson’s strategic case centers on the connection between pharmaceutical expertise and the practical delivery of care. In announcing the agreement, the company pointed to innovation in specialty, rare and orphan therapies, alongside the increasing need for alternate infusion services, as an attractive long-term opportunity. It also emphasized supporting patients, community providers, health systems, payers and biopharmaceutical manufacturers across multiple care settings. Option Care adds a clinical delivery platform to that ambition. Management expects the backing of CD&R and McKesson to support strategic investment and accelerate technology deployment aimed at improving outcomes and reducing the total cost of care. Those are stated objectives, not benefits investors should assume have already been achieved. For McKesson shareholders, the potential attraction is broader participation in specialty healthcare: not simply helping medicines move through the system, but holding an economic interest in a business that administers therapies to patients. There is an important accounting distinction. McKesson intends to account for its minority stake using the equity method, recording its share of Option Care’s net income or loss in “Other Income, net.” Investors should therefore not assume that Option Care’s revenue will simply be added to McKesson’s consolidated sales following closing. The bullish case is strategic exposure and potential earnings participation, not an automatic multibillion-dollar addition to reported revenue.

A Bullish Thesis, With Conditions

For Option Care shareholders, the agreement changes the investment question. The focus shifts from the company’s standalone growth prospects toward whether the transaction closes, when shareholders receive the cash consideration and how the market prices the remaining completion risk. The approximately 37% premium is measured against the October 5 closing price. It is not a guaranteed 37% return for someone purchasing OPCH after the announcement. Any prospective return would depend on the investor’s purchase price and successful completion of the deal. Several milestones remain. Shareholders must approve the transaction, regulators must provide required clearances and the parties must satisfy closing conditions. If completed, Option Care Health would become privately held and its shares would cease trading on Nasdaq. Investors also need to reset their expectations for the next earnings update. Option Care plans to release third-quarter 2026 results on November 4, but it has withdrawn its previously disclosed financial guidance and will not hold the accompanying live conference call. Earlier 2026 forecasts should therefore not be presented as current guidance. For McKesson, the longer-term opportunity remains compelling: an investment in a national infusion business that fits its stated specialty-care priorities, with a framework that could permit increased ownership later. But execution, financing economics, operating performance and regulatory outcomes will determine how much shareholder value the strategy ultimately produces. The company itself cautions that anticipated benefits and growth may not materialize. The positive takeaway is not that healthcare’s complications have disappeared. It is that McKesson and CD&R are committing capital to an established platform designed to deliver complex care closer to patients. For investors seeking substance beneath a specialty-healthcare growth story, that is a development worth watching.

The Sources

1. Yahoo Finance / Business Wire: CD&R and McKesson Corporation Sign Agreement to Acquire Option Care Health October 6, 2026.
2. McKesson Investor Relations: CD&R and McKesson Corporation Sign Agreement to Acquire Option Care Health October 6, 2026.
3. Option Care Health Investor Relations: Option Care Health Announces Financial Results for Fourth Quarter and Full Year 2025 February 24, 2026.
4. Il Sole 24 Ore Radiocor / Borsa Italiana: CD&R, McKesson to Buy Option Care Health in $5.8 Billion Deal October 6, 2026.
5. Reuters / Yahoo Finance: McKesson, CD&R to Buy Infusion Therapy Provider Option Care Health in $5.8 Billion Deal October 6, 2026.
6. Bloomberg / Yahoo Finance: McKesson, CD&R to Buy Option Care Health in $5.8 Billion Deal October 6, 2026.
7. Kirkland & Ellis: Kirkland Advises Option Care Health on $5.8 Billion Acquisition by CD&R and McKesson October 6, 2026.
8. Investing.com: CD&R and McKesson to Acquire Option Care Health for $5.8 Billion October 6, 2026.
9. Citybiz: CD&R and McKesson to Acquire Option Care Health for $5.8 Billion  October 6, 2026.